-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Hepatectomy is still the main strategy for the treatment of primary and metastatic liver tumors, although it still has a recurrence rate of 14-55%.
Hepatectomy is still the main strategy for the treatment of primary and metastatic liver tumors, although it still has a recurrence rate of 14-55%.
Recently, a study published in European Radiology evaluated the frequency of major complications after multi-probe stereotactic radiofrequency ablation (SRFA) in a large cohort of patients over the past 15 years, and clarified the risk factors for adverse events.
This study retrospectively included 793 consecutive patients (median age 65.
This study retrospectively included 793 consecutive patients (median age 65.
The 30-day mortality rate after SRFA was 0.
Figure 1 Multivariate logistic regression analysis forest plot of major complications.
Figure 1 Multivariate logistic regression analysis forest plot of major complications.
Figure 2 Overview of the most common major complications from 2004 to 2018.
Figure 2 Overview of the most common major complications from 2004 to 2018.
Stereotactic radiofrequency ablation of liver tumors is safe and reliable, and can expand the scope of conventional RFA treatment.
Original source:
Peter Schullian,Edward Johnston,Gregor Laimer,et al.
Peter Schullian,Edward Johnston,Gregor Laimer,et al.
Frequency and risk factors for major complications after stereotactic radiofrequency ablation of liver tumors in 1235 ablation sessions: a 15-year experience.
DOI: org/10.
1007/s00330-020-07409-0">10.
1007/s00330-020-07409-0 Frequency and Factors for Complications After Major Risk stereotactic ablation of liver tumors in radiofrequency ablation Sessions 1235:.
A 15-year preference Experience org/10.
1007/s00330-020-07409-0">10.
1007 / s00330-020-07409-0 in this message
